tbuckley/cabot-search huggingface dataset:
Characterization of Toxicokinetics and Toxicodynamics with Linear Systems Theory: Application to Lead-Associated Cognitive Decline
Authors: Jonathan M. Links, Brian S. Schwartz, David Simon, Karen Bandeen-Roche, Walter F. Stewart
Journal: Environmental Health Perspectives (2001)

We present a theoretical approach to analysis of toxicokinetics and toxicodynamics using linear systems theory. In our approach, we define two impulse response functions that characterize the kinetic behavior of an environmental agent in the body and the dynamic time-course behavior of its effect on the body. This approach provides a formalism for understanding the relation among exposure, dose, and cumulative biologically effective dose and for understanding the implications of an effect time-course on cross-sectional and longitudinal data analyses. We use lead-associated cognitive decline as a specific example where the approach may be applied.
Hypothalamic Hyperthyroidism (?)
Authors: James A. Pittman
Journal: New England Journal of Medicine (1972)

The cause of hyperthyroidism has been the source of speculation and experiment ever since Parry's observation of the disease in Elizabeth S. shortly after the frightening fall from her runaway wheelchair in 1803.1 Parry thought the basic defect was in the heart, but intimated a psychogenic origin. At least 10 types of hyperthyroidism are currently recognized: the diffuse toxic goiter of Graves's disease; toxic multinodular goiter; toxic uninodular goiter, or Plummer's disease; thyrotoxicosis factitia; tri-iodothyronine toxicosis (or "T3-toxicosis"); and the varieties associated with choriocarcinoma, hydatidiform mole, struma ovarii, metastatic thyroid carcinoma, and TSH-secreting pituitary tumors. Some of these . . .
Urologie und ihre Grenzgebiete: Dargestellt für praktische Ärzte.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Opacification from the Pulmonary Artery of an Anomalous Left Coronary Artery
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Climates of the United States.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A MODERN ABERNETHY
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SOCIETY PROCEEDINGS.
Authors: W. W. Jaggard
Journal: JAMA (1885)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Non-Hodgkin Lymphomas (NHL)-a Center for International Blood &amp; Marrow Transplant Research (CIBMTR) Analysis
Authors: Nilanjan Ghosh, Sairah Ahmed, Carlos Litovich, Kwang Woo Ahn, Manoj Khanal, Mohamed A Kharfan-Dabaja, Anna Sureda, Timothy S. Fenske, Mehdi Hamadani
Journal: Blood (2019)
A PERSONAL HYGIENIC EXHIBIT.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma
Authors: Roger Esteban-Fabró, Catherine E. Willoughby, Marta Piqué-Gili, Judit Peix, Carla Montironi, Jordi Abril-Fornaguera, Laura Torrens, Roser Pinyol, Josep M. Llovet
Journal: Journal of Hepatology (2020)
New Facility Helps Extend Medical Research
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Cost-effectiveness of Screening for Type 2 Diabetes
Authors: None The CDC Diabetes Cost-Effectiveness Study Group
Journal: JAMA (1998)

Context.—Type 2 diabetes mellitus is a common and serious disease in the United States, but one third of those affected are unaware they have it.Objective.—To estimate the cost-effectiveness of early detection and treatment of type 2 diabetes.Design.—A Monte Carlo computer simulation model was developed to estimate the lifetime costs and benefits of 1-time opportunistic screening (ie, performed during routine contact with the medical care system) for type 2 diabetes and to compare them with current clinical practice. Cost-effectiveness was estimated for all persons aged 25 years or older, for age-specific subgroups, and for African Americans. Data were obtained from clinical trials, epidemiologic studies, and population surveys, and a single-payer perspective was assumed. Costs and benefits are discounted at 3% and costs are expressed in 1995 US dollars.Setting.—Single-payer health care system.Participants.—Hypothetical cohort of 10,000 persons with newly diagnosed diabetes from the general US population.Main Outcome Measures.—Cost per additional life-year gained and cost per quality-adjusted life-year (QALY) gained.Results.—The incremental cost of opportunistic screening among all persons aged 25 years or older is estimated at $236,449 per life-year gained and $56,649 per QALY gained. Screening is more cost-effective among younger people and among African Americans. The benefits of early detection and treatment accrue more from postponement of complications and the resulting improvement in quality of life than from additional life-years.Conclusions.—Early diagnosis and treatment through opportunistic screening of type 2 diabetes may reduce the lifetime incidence of major microvascular complications and result in gains in both life-years and QALYs. Incremental increases in costs attributable to screening and earlier treatment are incurred but may well be in the range of acceptable cost-effectiveness for US health care systems, especially for younger adults and for some subpopulations (eg, minorities) who are at relatively high risk of developing the major complications of type 2 diabetes. Although current recommendations are that screening begin at age 45 years, these results suggest that screening is more cost-effective at younger ages. The selection of appropriate target populations for screening should consider factors in addition to the prevalence of diabetes.
Evaluation of an interferon inducer in viral respiratory disease
Authors: D. A. Hill
Journal: JAMA (1972)

To evaluate the effect of an interferon inducer on respiratory tract virus infection, poly l.poly C was administered intranasally to volunteers for a seven-day period beginning one day prior to inoculation of rhinovirus 13 or type A2 influenza virus/Hong Kong/68. In three separate trials, toxic effects were not detected and there was a small, but definite, reduction in symptoms of upper-respiratory tract illness associated with drug treatment. However, there was a variable effect on the pattern of virus infection. In only one of the two rhinovirus studies was a reduction of virus shedding observed. Treatment did not decrease the shedding of type A2 influenza virus. The minimal amounts of nasal interferon stimulated by the intranasally administered poly l.poly C may have been responsible for the less-than-optimal results obtained.
Next generation sequencing to reveal potentially actionable alterations in the majority of patients with hematologic malignancies.
Authors: Natalie Galanina, Aaron Goodman, Lisa Tran, Rafael Bejar, Michael Y. Choi, Razelle Kurzrock
Journal: Journal of Clinical Oncology (2017)

e23133 Background: Next generation sequencing (NGS) permits identification of genomic alterations that inform disease classification and prognosis and may also guide therapy selection. Methods: Using NGS (406 genes), we analyzed the clinical characteristics, genomic alterations, and potential actionability of 235 patients (pts) with diverse hematologic malignancies. Results: A total of 227 pts (96.5%) (59% men; median age 59 yrs) had adequate tissue for analysis. Most common diagnoses included myelodysplastic syndrome (22.9%), chronic lymphocytic leukemia (17.2%), non-Hodgkin lymphoma (13.2%), myeloproliferative neoplasm (9.2%), acute myeloid (11%) / lymphoid (8.8%) leukemia and multiple myeloma (7.5%). The majority of pts (N = 197/227 (86.8%)) harbored ≥1 genomic alteration(s); 164 pts (72%) had ≥1 potentially actionable alteration(s) targetable by an existing FDA-approved drug (mostly off label) or an investigational agent. A total of 551 distinct alteration s were seen with the most common involving TP53 (9.3%), TET2 (4.2%), DNMT3A (3.3%), ASXL1 (2.5%), MLL (2.5%), KRAS (2.2%). The vast majority of pts had unique molecular profile. Conclusions: About 96.5% of pts with hematologic malignancies have adequate tissue for NGS. Most pts had unique molecular signatures, and 72% had alterations that may be pharmacologically tractable. [Table: see text]
What stalked through the post office? What intellect, what calculation, number, measurement, replied?
Authors: W. B. Shelley
Journal: JAMA (1986)

<h3>To the Editor.—</h3> We applaud the botanical sleuthing of Fairbrothers and associates that led to the legume<i>Mucuna pruriens</i>as the cause of an unexplained "voodoo" pruritus in seven individuals in New Jersey.<sup>1</sup> I recalled a dramatic episode of itching that occurred in the Main US Post Office (30th Street Station) in Philadelphia one afternoon in March 1954. Twelve mailroom workers suddenly developed a severe generalized pruritus that rendered them incapable of anything but ceaseless scratching. Close questioning revealed that each of the 12 had handled or had been near a large, manila, paperwrapped carboard box moments before the itch developed. The box had just arrived from Jamaica and was addressed to us. A hurried telephone call to us provided prompt identification of the problem and reassurance as to its temporary nature. The box was filled with several thousand seed pods from the itch plant<i>M pruriens</i>(Fig 1),
A role for proteinase-activated receptor–1 in inflammatory bowel diseases
Authors: Nathalie Vergnolle, Laurie Cellars, Andrea Mencarelli, Giovanni Rizzo, Sunita Swaminathan, Paul Beck, Martin Steinhoff, Patricia Andrade-Gordon, Nigel W. Bunnett, Morley D. Hollenberg, John L. Wallace, Giuseppe Cirino, Stefano Fiorucci
Journal: Journal of Clinical Investigation (2004)

Proteinase-activated receptor–1 (PAR1), a G protein–coupled receptor activated by thrombin, is highly expressed in different cell types of the gastrointestinal tract. The activity of thrombin and of other proteinases is significantly increased in the colon of inflammatory bowel disease (IBD) patients. Since PAR1 activation in tissues other than the gut provoked inflammation, we hypothesized that PAR1 activation in the colon is involved in the pathogenesis of IBD. Here, we demonstrate that PAR1 is overexpressed in the colon of IBD patients. In mice, intracolonic administration of PAR1 agonists led to an inflammatory reaction characterized by edema and granulocyte infiltration. This PAR1 activation–induced inflammation was dependent on B and T lymphocytes. Moreover, PAR1 activation exacerbated and prolonged inflammation in a mouse model of IBD induced by the intracolonic administration of trinitrobenzene sulfonic acid (TNBS), while PAR1 antagonism significantly decreased the mortality and severity of colonic inflammation induced by TNBS and dextran sodium sulfate. In these 2 models, colitis development was strongly attenuated by PAR1 deficiency. Taken together, these results imply an important role for PAR1 in the pathogenesis of experimental colitis, supporting the notion that PAR1 inhibition may be beneficial in the context of IBD and possibly in other chronic intestinal inflammatory disorders.
Reply to capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?
Authors: D.J. Storey, M. Sakala, C.M. McLean, H.A. Phillips, L.K. Dawson, L.R. Wall, M.T. Fallon, S. Clive
Journal: Annals of Oncology (2011)
Defensive medicine and obstetrics
Authors: L. M. Baldwin
Journal: JAMA (1995)

<h3>Objective.</h3> —To test the hypothesis that physicians with greater malpractice claims exposure, either through personal experience or in their practice environment, will use more prenatal resources and have a higher cesarean delivery rate than physicians with lesser claims exposure. <h3>Design.</h3> —Retrospective cohort study using county malpractice defendant rate data from the Washington State Physicians Insurance and Exchange Association and prenatal care, delivery method, and self-reported obstetric suit experience data from the Content of Obstetrical Care Study database. <h3>Setting.</h3> —Washington State obstetric practices. <h3>Participants.</h3> —Stratified random samples of obstetrician-gynecologists and family physicians. <h3>Main Outcome Measures.</h3> —The rates of obstetric ultrasound use, referral and consultation, prenatal care resource use, and cesarean delivery. <h3>Results.</h3> —After controlling for patient, physician, and sociodemographic characteristics, we found no difference in prenatal resource use or cesarean delivery rate for low-risk patients between physicians with more and less exposure to malpractice claims. <h3>Conclusions.</h3> —This study does not support an association between the malpractice experience or exposure of individual physicians and an increase in the use of prenatal resources or cesarean deliveries for the care of low-risk obstetric patients. (<i>JAMA</i>. 1995;274:1606-1610)
Manuscripts Approved (or JNCI, October 1 to November 1, 1964
Journal: JNCI Journal of the National Cancer Institute (1964)

Manuscripts Approved (or JNCI, October 1 to November 1, 1964 Get access JNCI: Journal of the National Cancer Institute, Volume 33, Issue 6, December 1964, Page 1082, https://doi.org/10.1093/jnci/33.6.1082-a Published: 01 December 1964
THE PROBLEM OF GOUT
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Responce
Authors: PHILIP J. JOHNSON, ROGER WILLIAMS
Journal: JNCI Journal of the National Cancer Institute (1990)

Journal Article Responce Get access PHILIP J. JOHNSON, PHILIP J. JOHNSON Search for other works by this author on: Oxford Academic PubMed Google Scholar ROGER WILLIAMS ROGER WILLIAMS Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 22, 21 November 1990, Pages 1784–1785, https://doi.org/10.1093/jnci/82.22.1784-a Published: 21 November 1990